[New molecular marker in dialysis setting--misfolded beta 2-microglobulin]

Rinsho Byori. 2004 Apr;52(4):362-7.
[Article in Japanese]

Abstract

More than 25 clinical settings in amyloidosis have been acknowledged in which a peculiar criminal protein, a precursor protein, has been identified. As of now, however, the mechanism of amyloidogenesis, by which a precursor protein is transformed irreversibly into an amyloid protein, remains to be clarified. We speculated that a study of the molecular conformation of beta 2-microglobulin (beta 2 m), a precursor protein in dialysis-related amyloidosis (DRA), might provide a typic model of amyloidogenesis in other precursor proteins. Therefore, we investigated the misfolding of beta 2 m in DRA using a specific monoclonal antibody against C-terminal peptide 92-99 of beta 2 m. Our study indicated the possibility that the monoclonal antibody specific for C-terminal 92-99 of beta 2 m can detect a pre-amyloid state in amyloidogenesis in vivo, which might take place in the extravascular space.

Publication types

  • English Abstract

MeSH terms

  • Amyloidosis / diagnosis*
  • Amyloidosis / etiology*
  • Antibodies, Monoclonal
  • Biomarkers
  • Humans
  • Protein Conformation
  • Protein Folding*
  • Renal Dialysis / adverse effects*
  • beta 2-Microglobulin* / chemistry
  • beta 2-Microglobulin* / immunology

Substances

  • Antibodies, Monoclonal
  • Biomarkers
  • beta 2-Microglobulin